© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Dementia and Alzheimer Disease
The NeurologyLive dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
NeurologyLive Friday 5 — July 30, 2021
July 30, 2021
Article
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 30, 2021.
Pimavanserin Safety Data and Future Research: Clive Ballard, MD
July 30, 2021
Video
Clive Ballard, MD, spoke on the safety data of pimavanserin, which was presented at the 2021 AAIC meeting, held from July 26-30.
Identifying High-Potential Drugs to Repurpose for Alzheimer Disease: Feixiong Cheng, PhD
July 30, 2021
Video
The assistant professor at Cleveland Clinic discussed key factors to consider when choosing repurposed drugs that could show max potential in treating Alzheimer disease.
Episode 43: Is Telehealth Here to Stay for Alzheimer Disease Care?
July 30, 2021
Podcast
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jessica Zwerling, MD, MS.
Aducanumab Phase 4 Real-World Observational Study Announced
July 29, 2021
Article
The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.
Positive Effects of Pimavanserin for Patients With AD: Clive Ballard, MD
July 29, 2021
Video
Clive Ballard, MD, professor of age related diseases at University of Exeter, commented on the potential impact that the approval of pimavanserin would have for patients if approved for dementia-related psychosis.
Methylphenidate Shows Small to Medium Benefit in Treating Alzheimer Apathy
July 29, 2021
Article
The effect of methylphenidate on Alzheimer disease apathy was observed at 2 months and was sustained throughout the 6 months of the study.
Baseline Characteristics Announced for Lecanemab Phase 3 Study
July 28, 2021
Article
Participants will be enrolled for 18 months, with baseline data provided and compared to the lecanemab phase 2 study cohort.
Advantages of CPAD Consortium: Sudhir Sivakumaran, PhD; Klaus Romero, MD, MS, FCP
July 28, 2021
Video
The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.
Relapse Rates and Effects of Dementia-Related Psychosis: Clive Ballard, MD
July 28, 2021
Video
Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.